HOME >> BIOLOGY >> NEWS
Novel Liver Steroid Slows Brain Tumor Growth

Laboratory studies at Johns Hopkins have dramatically confirmed the power of a chemical discovered from the liver of sharks to slow the formation of new blood vessels destined to feed brain cancers as well as other tumors.

Squalamine, previously shown to have antibiotic and anti-cancer activity, inhibited the growth of brain cancers called gliomas implanted in the flanks of rats by disabling blood vessel growth, or angiogenesis, say the authors of the studies, published in the July 1 issue of the journal Cancer Research.

"Our results suggest that squalamine may be well suited for humans in the treatment of brain tumors and other diseases characterized by and dependent on new blood vessel growth," says Henry Brem, M.D., director of neurosurgical oncology at Hopkins and senior author of the study. "It dramatically slowed blood vessel formation without damaging healthy cells or embryonic development."

Named for the shark genus Squalus, squalamine was discovered in 1992 by scientists who founded Magainin Pharmaceuticals, which processes the chemical and funded the Hopkins studies. Squalamine is the first of a new class of naturally occurring molecules, aminosterols, under development for human therapies.

Squalamine is isolated from the tissues of the dog shark. It blocks or interferes with several steps in a cascade of events involved in blood vessel growth. Based on the Hopkins laboratory work, it is currently in Phase I clinical trials at the University of Texas (San Antonio) and at Georgetown Cancer Center.

In laboratory tests, squalamine proved to be as effective as the chemotherapeutic agent carmustine in slowing the growth of gliomas, the most common and deadly brain tumors, in rats. Squalamine also slowed the growth of new blood vessels caused by tumors in rabbits' eyes, slowed the growth of endothelial cells in rat brain tissue and constricted the tiny blood vessels in chick embryos. The latter ves
'"/>

Contact: Karen Infeld
kinfeld@jhmi.jhu
(410)955-1534
Johns Hopkins Medical Institutions
1-Jul-1998


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum ... will be featured in multiple sessions at this week’s Association of Clinical Research ... to best practices in clinical research. , "We are excited to present subject matter ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, ... funding to three startups through the UConn Innovation Fund. The $1.5 million UConn ... affiliated with UConn. , The UConn Innovation Fund provides investments of up to ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... this new webinar will explore challenging patient cases when screening for direct oral ... there may be a need for bridging parental anticoagulation especially for those at ...
(Date:4/20/2017)... ... 2017 , ... NetDimensions appoints Bill Mastin, a learning technology veteran, as its ... in the learning technologies industry, Mastin joins NetDimensions from the New York office of ... At LEO, Mastin served as SVP of the North America offices and prior to ...
Breaking Biology Technology:
Cached News: